Sai Life Sciences
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Sai Life Sciences is navigating a transformative phase as it evolves into a multi-modality CRDMO, with management emphasizing strategic investments in capacity expansion and integrated service offerings. The company's commitment to a 15-20% revenue growth target and 28-30% EBITDA margin reflects confidence in its long-term fundamentals, despite acknowledging potential near-term operational inefficiencies. Recent developments, including a significant capex plan of ₹1100-1300 Crore aimed at nearly doubling manufacturing capacity by FY27, support Vista's forecast of moderating revenue growth and margin pressures. The expanding opportunities for Indian CDMOs, driven by global supply chain diversification, further bolster the outlook. However, challenges such as raw material supply constraints and geopolitical factors remain pertinent. Over the next 12-24 months, key opportunities include deepening relationships with large pharmaceutical companies and leveraging next-generation technologies, while watchpoints include the impact of government regulations on raw material availability and the execution of the ambitious capex plan
Why We Like This Stock
- Management's commitment to a 15-20% revenue growth target and 28-30% EBITDA margin indicates strong long-term fundamentals
- Significant capex investments aimed at capacity expansion are expected to enhance competitive positioning
- The favorable industry dynamics for Indian CDMOs present substantial growth opportunities
Things To Watch Out For
- Raw material supply constraints due to government regulations may hinder production capabilities
- Potential operational inefficiencies from the ongoing capex cycle could impact near-term performance
- Geopolitical factors and market volatility may pose risks to revenue stability
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,465 | 1,695 | 2,192 | 2,574 | 3,047 |
| Profit Before Tax (Cr.) | 109 | 230 | 474 | 766 | 845 |
| PBT Margin | 7.4% | 13.6% | 2162.4% | 29.8% | 27.7% |
| Net Profit (Cr.) | 102 | 195 | 384 | 622 | 686 |
| Earnings Per Share | 4.8 | 9.2 | 18.1 | 29.3 | 32.3 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| HDFC Securities | ▲ Buy | 1,280 | 18-May-2026 |
| Jeffries | ▲ Buy | 1,300 | 01-Apr-2026 |
| Kotak Securities | ▲ Buy | 1,225 | 18-May-2026 |
| Moneycontrol | ► Equalweight | nan | 18-May-2026 |
| Morgan Stanley | ▲ Overweight | 1,160 | 08-Apr-2026 |
Company Overview
Show Company Profile
Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It provides medicinal chemistry, pharmacokinetics, manufacturing, and contract development services. The company was formerly known as SAI Advantium Pharma Limited and changed its name to Sai Life Sciences Limited in July 2006. Sai Life Sciences Limited was incorporated in 1999 and is based in Hyderabad, India.